Proposed nuclear safety rules threaten to stall Novartis’ Pluvicto expansion
Novartis’ flagship radioligand therapy Pluvicto entered a rapid growth phase recently, driven by FDA approvals in earlier-stage prostate cancer and broader uptake in community settings. But a regulatory overhaul proposed by federal nuclear authorities now threatens to derail that momentum, potentially raising administrative hurdles that experts say could force clinics to rethink patient care…
We haven't written up this one. Fierce Healthcare has the full story — the link below goes straight to it.
